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Osteoclastogenesis is dependent on distinct stimuli that prime and activate osteoclast diﬀerentiation. One cytokine needed to prime
monocytes for osteoclastogenesis is TGF-b, which enables and augments RANKL and TNF-a-induced osteoclast diﬀerentiation. How-
ever, the precise time-period during which this occurs and the molecular mechanism mediating this action are unknown. We report here
TGF-b prime monocytes for osteoclast formation within 24 h by regulating expression of NFATc1, a key osteoclastic transcription fac-
tor. TGF-b directly induces cytoplasmic NFATc1 expression within 24 h, but is unable to stimulate NFATc1 nuclear translocation. Fur-
thermore, RANKL-induced NFATc1 expression is dependent on the presence of TGF-b during the early stages of osteoclastogenesis.
Similarly, TNF-a activates osteoclastogenesis by stimulating translocation of TGF-b-induced NFATc1. In light of these ﬁndings, it is
apparent that osteoclast formation is dependent on coordinated interactions between TGF-b and RANKL/TNF-a that regulate the
expression and intracellular distribution of NFATc1 during early stages of osteoclast diﬀerentiation.
 2007 Elsevier Inc.
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Open access under CC BY license.Bone is optimized for the skeleton’s mechanical and
mineral storage roles. Changes in physical activity or circu-
lating calcium elicit a remodeling response that maintains
structural competency or restores serum calcium. This is
mediated by osteoblasts, which synthesize new bone, and
osteoclasts, which resorb bone. It is critical that osteoclast
formation is tightly regulated as excessive resorption can
cause disorders such as osteoporosis.
Activation of osteoclast diﬀerentiation from monocytic
precursors is dependent on a balance between levels of
the osteoblast-derived cytokine, receptor activator of
nuclear factor-jB ligand (RANKL) and its soluble decoy
receptor, osteoprotegerin (OPG). Resorptive stimuli
increase RANKL and suppress OPG expression to activate
osteoclast formation [1,2]. Subsequent binding of RANKL0006-291X  2007 Elsevier Inc.
doi:10.1016/j.bbrc.2007.11.120
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Open access under CC BY license.to its receptor RANK induces osteoclastic gene transcrip-
tion via signaling intermediates including nuclear factor-
jB (NFjB), nuclear factor of activated T cells c1
(NFATc1), and AP-1 (see [3]).
Alongside RANKL, monocytes require further bone-
derived inputs to prime and enhance their response to
RANKL. Without this enabling input osteoclastogenesis
will not occur. This is supported by the observation that
RANK expressing monocytes do not form osteoclasts out-
side of bone even in the presence of RANKL at doses far
greater than needed to induce diﬀerentiation in vitro [4].
One key enabling factor is transforming growth factor-b
(TGF-b), which primes and enhances the response of
monocytes to RANKL or TNF-a [4–9]. Precursors failing
to receive this priming stimulus will not develop into osteo-
clasts [4–6]. This facilitative action is in part achieved by
antagonizing the anti-osteoclastic action of inﬂammatory
cytokines, which would otherwise prime precursors to mac-
rophage lineages [10,11]. However, this does not represent
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enhances osteoclastogenesis, as TGF-b also augments
osteoclast formation in the absence of inﬂammatory cyto-
kines [5,9].
TGF-b and RANKL utilize overlapping intracellular
signaling cascades [3]. These regulate osteoclastic gene
expression via key transcription factors such as NFATc1
and c-fos. Like TGF-b, these transcription factors are
essential for osteoclast formation [12,13]. It is possible,
therefore, that TGF-b’s enabling and augmentative eﬀect
could be mediated via an action on these transcription fac-
tors. To investigate this, it was ﬁrst necessary to determine
the time-period during which TGF-b enables osteoclasto-
genesis, and establish whether TGF-b-induced signals are
essential at the inception of osteoclastogenesis or necessary
throughout the diﬀerentiation process. Once this had been
established, the ability of TGF-b to modify NFATc1 and c-
fos expression during this period was examined.
Materials and methods
Media and reagents. Stroma depleted nonadherent, M-CSF dependent
bone marrow monocytes (BMM) and RAW264.7 murine monocytes
(ATCC, UK) were incubated in MEM and Earle’s salts (EMEM) sup-
plemented with 10% FCS (Autogen Bioclear, UK), 2 mmol/l glutamine,
100 IU/ml benzylpenicillin, and 100 mg/ml streptomycin (all from Sigma,
UK). Incubations were performed at 37 C in 5% CO2, and cultures fed
every 2–3 days. Recombinant humanM-CSF, soluble human recombinant
RANKL, recombinant human OPG, and murine recombinant TGF-b1
were obtained from Insight Biotechnology. Anti-TNF-a antibody and
pan-speciﬁc TGF-b antibody were purchased from R&D systems. Anti-
NFATc1 antibody was obtained from Santa Cruz Biotechnology. All
other reagents were obtained from Sigma unless stated.
Isolation of BMM. Female MF-1 mice (4–6 weeks old) were killed by
cervical dislocation. Femur and tibia were removed and dissected free of
soft tissue. The bone ends were cut and marrow ﬂushed out with medium
199. Cells were washed, resuspended in EMEM, and incubated for 24 h in
M-CSF (5 ng/ml) at a density of 3 · 105/ml. After 24 h, BMM were har-
vested, washed, and incubated as described below.
Northern analysis. Total RNA was prepared from BMM (2 · 105/ml)
incubated for 2 days in M-CSF (10 ng/ml) and then treated with M-CSF
and combinations of RANKL and TGF-b for 24 h, with or without OPG
(100 ng/ml), and anti TNF-a antibody (10 mg/ml) using a commercially
available kit. Fifteen micrograms of total RNA was denatured, separated
on a 1.2% agarose-formaldehyde gel, transferred to a Hybond–N mem-
brane (Amersham International), and hybridized for 16 h at 42 C with
32P-labeled cDNA probes for murine NFATc1, c-fos, and b-actin pre-
pared by the random primer method. After hybridization membranes were
washed at 42 C (2· SSPE and 0.1% SDS; 1· SSPE and 0.1% SDS; 0.5·
SSPE and 0.1% SDS) and autoradiographed using Hyperﬁlm.
QuantitativeRT-PCR.BMM(2 · 105/ml)were incubated for 2dayswith
M-CSF (10 ng/ml) and then treated with combinations of M-CSF (10 ng/
ml), RANKL (30 ng/ml), TGF-b1 (0.4 ng/ml) or pan-speciﬁc TGF-b anti-
body (10 mg/ml) for 24 h. Total RNAwas extracted from these cultures and
reverse transcribed with M-MLV. Real-time PCR was performed on an I-
cycler (Bio-Rad,UK)using theDNA-binding dyeSYBRgreen for detection
of PCR products. A total of 2 ll of external plasmid standard or cDNAwas
added to a ﬁnal reaction volume of 25 ll containing 0.05 U/ll Taq, SYBR
green, and speciﬁc primers (0.2 lM). Primers used were as follows: murine
NFATc1 sense 5 0-CCGTTGCTTCCAGAAAATAACA-3 0; NFATc1
antisense, 5 0-TGTGGGATGTGAACTCGGAA-3 0; b-actin sense 5 0-GT
CATCACTATTGGCAACGAG-3 0; and antisense 5 0-CCTGTCAGC
AATGCCTGGTACAT-3 0. Reaction conditions were 95 C for 3 min,
followed by 35 cycles of 95 C for 20 s, 59 C for 20 s, and 72 C for 20 s. Foreach sampleNFATc1mRNA levels were expressed as relative copy number
normalized to 10 b-actin mRNA copies.
Immunoﬂuorescence. BMM or RAW 264.7 cells were seeded onto glass
coverslips and incubated in M-CSF (30 ng/ml) or RANKL (100 ng/ml) for
5 days to generate osteoclasts. Cells were washed in EMEM, incubated in
M-CSF for 1 h to remove RANKL, and then stimulated with TGF-b
(1 ng/ml) for 30 min. The cellular distribution of NFATc1 was assessed as
follows. Coverslips were removed, washed in PBS, ﬁxed in 4% parafor-
maldehyde, permeabilized with 0.1% Triton X-100, incubated with 1%
goat serum, and incubated with a speciﬁc anti-mouse NFATc1 mono-
clonal antibody diluted 1:50 in 1% goat serum for 1 h. Cells were washed
in PBS, incubated for 2 h with a biotinylated goat anti-mouse secondary
(Vector Labs, USA), and then incubated for 2 h with ﬂuorescein conju-
gated streptavidin (Vector Labs, USA). Fluorescence was visualized using
a Leica HC microscope. Photographs were taken with a JVC digital
camera linked to image pro-plus so at a magniﬁcation of 400· or 1000·.
Assessment of osteoclast formation. Osteoclast formation was evaluated
using the speciﬁc osteoclast marker tartrate resistant acid phosphatase
(TRAP) [14]. After incubation, cells were washed in PBS, ﬁxed in 10%
formalin, washed, and stained for TRAP. Cells were counterstained with
hematoxylin and examined at 40· magniﬁcation on a light microscope
ﬁtted with an eyepiece graticule.
Statistical analysis. Diﬀerences between groups were assessed using
ANOVA (Statview; Abacus concepts, USA). A diﬀerence of p < 0.05 was
considered signiﬁcant.
Results and discussion
TGF-b commits monocytes to the osteoclastic lineage within
24 h
To establish when TGF-b commits monocytes to the
osteoclast lineage BMM were pre-incubated with TGF-b
for 1–72 h, and then cultured with combinations of M-
CSF, RANKL, and IFN-c. BMM exposed to TGF-b for
only part of the pre-incubation period were grown with
M-CSF alone for the remainder of the pre-treatment. Fol-
lowing pre-treatment all cultures were incubated for 5 days
with combinations of M-CSF, RANKL, TGF-b, and IFN-
c.
As shown previously, IFN-c suppressed RANKL-
induced osteoclast formation (Fig. 1) [15]. Pre-incubation
with TGF-b for 1–6 h was unable to overcome the inhibi-
tory action of IFN-c. Whereas, pre-incubation with
TGF-b for 24 h completely abolished IFN-c’s anti-osteo-
clastic action. Pre-incubating for 48 or 72 h did not further
enhance osteoclast formation, suggesting that the intracel-
lular events mediating TGF-b’s augmentative action are
completely active within 24 h of TGF-b exposure. There-
fore, TGF-b facilitates the initial events governing osteo-
clast formation.
TGF-b induces NFATc1 expression within 24 h and enables
RANKL induced NFATc1 expression
Binding of RANKL to RANK activates several tran-
scription factors responsible for promoting osteoclastic
gene expression. These are not all activated within the
same time-frame: early-response factors, such as c-fos,
are activated before late-response factors, such as
NFATc1 [16]. Like TGF-b, these are essential for osteo-
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Fig. 1. Pre-incubation with TGF-b for 24 h is suﬃcient to commit BMM to the osteoclast lineage. BMM were pre-treated with M-CSF with or without
TGF-b for 1, 6, 24, 48, and 72 h to determine the minimum period suﬃcient for TGF-b to antagonize the anti-osteoclastic action of IFN-c. All cultures
were pre-treated for 72 h irrespective of whether they received TGF-b during pre-treatment regime. Cultures exposed to TGF-b for a proportion of the
pre-incubation period had TGF-b removed after the relevant exposure time and replaced with M-CSF. Following pre-treatment all cultures were washed
and incubated for 5 days with combinations of M-CSF, RANKL, TGF-b, and IFN-c. Controls consisted of BMM incubated with TGF-b throughout the
pre-incubation period and exposed to M-CSF, RANKL, and TGF-b in the diﬀerentiation period. Values are expressed as means ± SEM of four separate
experiments n = 20, *p < 0.05 versus group pre-treated with M-CSF alone then cultured in M-CSF, RANKL, and IFN-c.
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will not undergo osteoclast formation [12,13], whereas
ectopic NFATc1 expression under certain circumstances
may be suﬃcient for osteoclast diﬀerentiation in the
absence of activating cytokines [17]. NFATc1 is therefore
critical for osteoclastogenesis.
In light of this, we examined the eﬀect of TGF-b on
NFATc1 expression. NFATc1 mRNA expression was
low in non-committed BMM, whereas RANKL induced
detectable levels within 24 h, which was strongly aug-
mented in the presence of TGF-b (Fig. 2A). Further-
more, TGF-b itself induced a signiﬁcant increase in
NFATc1 expression (Fig. 2A and C) even in the presence
of OPG and anti-TNF-a antibody (Fig. 2B). This sug-
gests that TGF-b is able to directly induce NFATc1
and also enhance RANKL-induced NFATc1 expression
during the time-period when it enables and augments
osteoclast diﬀerentiation.
TGF-b and NFATc1 are both essential for osteoclasto-
genesis, as sequestering TGF-b suppresses RANKL-
induced osteoclast diﬀerentiation [5], while RANKL stim-
ulated osteoclastogenesis is impaired in NFATc1 deﬁcient
monocytes [18]. Thus, it is conceivable that TGF-b’s facil-
itative action may depend on its ability to regulate
RANKL-induced NFATc1 expression during initial stages
of osteoclast diﬀerentiation. To assess this, the ability of
RANKL to induce NFATc1 was assessed in cultures in
which TGF-b was removed using pan-speciﬁc TGF-b anti-
body. This prevented RANKL-induced NFATc1 expres-
sion, with levels not signiﬁcantly diﬀering from M-CSF-
treated controls (Fig. 2B and C), suggesting that
RANKL-induced NFATc1 expression, a critical step in
the molecular events determining osteoclast formation, isdependent on TGF-b’s enabling action and without this
input osteoclast formation cannot occur.
This dependence could represent one of two possibili-
ties. First, it could reﬂect the established requirement of
TGF-b for osteoclast diﬀerentiation; the lack of expression
occurring as a secondary consequence of the block in
osteoclast formation. On the other hand, it could be the
primary mechanism by which TGF-b enables osteoclasto-
genesis: TGF-b providing an input to induce NFATc1
expression in non-committed precursors. NFATc1 is there-
after available to be activated by RANKL to propagate the
chain of downstream events that result in osteoclast forma-
tion. At present, it is not possible to draw a ﬁrm conclusion
on which interpretation is correct; however, the ability of
TGF-b to directly stimulate NFATc1 expression is more
in keeping with the second hypothesis.
TGF-b does not induce c-fos expression or NFATc1 nuclear
translocation
While TGF-b induces NFATc1 expression it is unable to
stimulate osteoclastogenesis. Previous studies suggest that
NFATc1 is not only necessary for osteoclast formation
but may be suﬃcient to stimulate osteoclastogenesis on
its own [19]. If true, then it raises the question of why
TGF-b does not stimulate osteoclastogenesis in the absence
of additional activating stimuli. There are several explana-
tions for this; ﬁrst TGF-b may not induce all the transcrip-
tion factors that cooperate with NFATc1 to promote
osteoclastic gene expression such as members of the AP-1
family [12,18]. One key AP-1 member involved in osteo-
clast diﬀerentiation is c-fos, which is induced in monocytes
by RANKL [20]. However, the eﬀect of TGF-b on c-fos
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Fig. 2. TGF-b directly induces NFATc1 mRNA expression in BMM
within 24 h and enables RANKL-induced NFATc1 expression. (A) Total
RNA was prepared from BMM incubated with M-CSF and combinations
of RANKL and TGF-b for 24 h and Northern analysis performed for
NFATc1 and b-actin. (B) Total RNA was isolated from BMM incubated
with M-CSF and combinations of TGF-b with or without OPG and anti-
TNF-a antibody for 24 h. Northern analysis was then performed for
NFATc1 and b-actin. (C) BMM were incubated in M-CSF for 2 days.
Cultures were treated with M-CSF and combinations of RANKL and
TGF-b, with or without OPG or anti-TGF-b antibody for 24 h. Total
RNA was extracted and analyzed using quantitative RT-PCR. Results are
expressed as NFATc1 copy number per 106 b-actin and are means of three
separate experiments ± SEM, *p < 0.05 versus all groups.
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Fig. 3. TGF-b does not induce c-fos expression or nuclear translocation of
NFATc1. (A) Total RNA was prepared from BMM incubated with M-
CSF; M-CSF, and RANKL or M-CSF, RANKL, TGF-b, OPG, and anti-
TNF-a neutralizing antibody for 24 h. Northern analysis was then
performed for NFATc1 and b-actin. (B) Immunolocalization of NFATc1
i, BMM incubated with M-CSF; magniﬁcation 40·. ii and iii, BMM
treated with M-CSF and TGF-b for 45 min; magniﬁcation 40· and 100·.
iv, RAW264.7 cells treated with TGF-b for 45 min; magniﬁcation 40·.
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NFATc1 expression it may not provide the necessary
inputs to stimulate its nuclear translocation. This is regu-
lated by post-translational modiﬁcations that expose
nuclear localization signals [21]. Without these modiﬁca-
tions osteoclastic gene expression cannot proceed
[12,19,22]. Thus, it is conceivable that while TGF-b induces
NFAT expression it may not necessarily stimulate nuclear
translocation.
Therefore, to assess these possibilities we examined the
ability of TGF-b to induce c-fos expression and NFATc1nuclear translocation. To examine c-fos expression BMM
were incubated for 24 h with M-CSF and TGF-b in the
presence of OPG and anti-TNF-a antibody to sequester
any RANKL or TNF-a present in the culture environment.
c-fos mRNA was not detectable in control cultures treated
with M-CSF alone, but was readily detectable in cultures
incubated with M-CSF and RANKL for 24 h (Fig. 3A).
However, in contrast to its action on NFATc1, TGF-b
was unable to induce c-fos expression in BMM (Fig. 3A).
To examine the ability of TGF-b to regulate NFATc1
migration, ﬂuorescent immunocytochemistry was used to
determine the distribution of NFATc1 in BMM treated
with or without TGF-b. In keeping with the Northern anal-
ysis data, NFATc1 immunoﬂuorescence was not detected
in unstimulated BMM (Fig. 3Bi), whereas BMM or
RAW264.7 cells incubated with TGF-b displayed intense
NFATc1 staining (Fig. 3Bii–iv). Staining was predomi-
nantly cytoplasmic, suggesting that while TGF-b increases
NFATc1 protein levels it is not suﬃcient to induce nuclear
translocation. Therefore, although TGF-b may be required
for NFATc1 expression it is not suﬃcient to induce its acti-
vation and nuclear translocation in monocytes. This sug-
gests that the inability of TGF-b to stimulate
osteoclastogenesis is due to a combination of failing to
induce c-fos and activate NFATc1 nuclear translocation.
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induced osteoclastogenesis
Other cytokines in addition to RANKL are also capable
of activating osteoclast formation. One such factor, TNF-
a, directly stimulates osteoclast formation from BMM [23],
and may have a role in excessive osteoclast formation seen
in post-menopausal osteoporosis and rheumatoid arthritis
[24]. TGF-b is also essential for TNF-a-induced osteo-
clastogenesis [4]. TNF-a binding to its receptor activates
a cascade of intracellular signals but in contrast to
RANKL it does not activate TRAF6 which is required
for the initial induction of NFATc1 expression [12]. As
NFATc1 is critical for the early stages of osteoclast diﬀer-
entiation and TGF-b is able to directly induce NFATc1
expression within 24 h we examined the possibility that
TGF-b-induced NFATc1 expression has a role in TNF-a
activated osteoclast formation.
TNF-a did not signiﬁcantly increase NFATc1 expres-
sion in monocytes, levels not diﬀering from M-CSF con-
trols (Fig. 4A). In contrast, TGF-b directly induced a
signiﬁcant 4.6-fold increase in NFATc1 expression within
24 h (Fig. 4A), and similar levels were noted in cultures
incubated with both TGF-b and TNF-a (Fig. 4A). Thus,
the inability of TNF-a to induce NFATc1 suggests that
another TGF-b may enable TNF-a-induced osteoclast for-
mation by providing NFATc1 during the initial stages of0
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Fig. 4. TGF-b facilitates NFATc1 expression in TNF-a-induced osteo-
clasts. (A) BMM were incubated in M-CSF for 2 days. Cultures were
treated with M-CSF and combinations of TNF-a, TGF-b, pan-speciﬁc
neutralizing TGF-b antibody, and OPG for 24 h. Total RNA was
extracted and NFATc1 expression analyzed using quantitative real-time
PCR. Results are means of separate experiments expressed as NFATc1
copy number per 106 b-actin ± SEM. *p < 0.05 versus M-CSF, M-CSF
plus RANKL, and M-CSF, RANKL plus TGF-b antibody. (B) Immu-
nolocalization of NFATc1 in RAW264.7 cells incubated for 48 h in TNF-
a (i), TGF-b (ii) or TGF-b for 48 h followed by 45 min with TNF-a (iii).diﬀerentiation. This is further underlined by a 2.9-fold
reduction in NFATc1 expression in TNF-a treated cultures
incubated with pan-speciﬁc TGF-b antibody (p < 0.05),
suggesting that basal levels of NFATc1 expression are to
a large extent attributable to TGF-b present within the cul-
ture environment (Fig. 4A). The inability of TNF-a to
induce NFATc1 expression without TGF-b being present
was conﬁrmed in immunoﬂuorescence studies (Fig. 4B).
No appreciable diﬀerence in staining intensity was seen in
control cultures compared with those treated with TNF-a
(Fig. 4Bi and ii). However, while TNF-a is unable to
induce NFAT expression, it is able to stimulate nuclear
accumulation of NFATc1 in cultures that have been pre-
treated with TGF-b (Fig. 4Biii). TNF-a activated osteo-
clast diﬀerentiation would therefore appear to rely on
TGF-b to promote an initial cytoplasmic increase in
NFATc1, which is subsequently translocated to the nucleus
under the inﬂuence of activating stimuli provided by TNF-
a. Therefore, the formation of osteoclasts in inﬂammatory
conditions such as rheumatoid arthritis may be controlled
by a reciprocal interaction between TGF-b and TNF-a
on NFATc1 expression and activity; TGF-b promoting
cytoplasmic accumulation of NFATc1 which subsequently
translocates to the nucleus under the inﬂuence of TNF-a.
To conclude our data clearly show that TGF-b inﬂuences
osteoclast formation by regulating NFATc1 expression, a
critical component of the osteoclastic transcriptional
machinery. TGF-b acts directly on non-committed mono-
cytes to enhance RANKL-induced NFATc1 expression;
moreover, RANKL is unable to induce NFATc1 in the
absence of TGF-b. Thus, both the augmentative and
enabling action of TGF-b on osteoclast formation may be
mediated through its ability to control cytoplasmic levels
of NFATc1 during the early stages of osteoclastogenesis.
Furthermore, it is likely that TGF-b may facilitate TNF-
a-induced osteoclast formation through a very similar
NFATc1-dependent mechanism. Formation of osteoclasts
during physiological remodeling and inﬂammatory condi-
tions may be dependent on a coordinated interaction
between TGF-b and RANKL/TNF-a, which regulates the
expression and intracellular distribution of NFATc1 during
the initial stages of osteoclastogenesis.Acknowledgment
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